Suven Life Sciences Limited · NSE:SUVEN
Suven Life Sciences — Q1 FY2020 Earnings Presentation
13 slides from Suven Life Sciences's earnings presentation, Aug 14, 2019
Slide 1: SUVEN Life Sciences – Communication to investors
SUVEN Life Sciences Communication to investors June 2019 14-Aug-19 2019-20 Q1 results
Slide 2: Risk statement
Risk statement Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in
Slide 3: Financial Quick View – Quarter 1 June 2019
FINANCIAL QUICK VIEW Quarter 1 – June 2019 Q1-FY20 Q1-FY20 to Q4-FY19 to Q1-FY19 Growth in Revenue -21.42% 1.10% Growth in PAT -16.62% 47.38% Growth in EBIDTA -14.68% 40.21% Growth Pre-R&D -16.37% 28.89% EBIDTA Increase in R&D costs -26.68% -18.06% 14-Aug-19 2019-20 Q1 results
Slide 4: Major Profitability Ratios
MAJOR PROFITABILITY RATIOS 30 Jun 2019 31 Mar 2019 30 Jun 2018 PAT to Income 28.29% 26.47% 19.41% EBIDTA to 46.06% 42.42% 33.21% Income Cash Flow to 31.04% 28.60% 22.16% Income Pre-R&D 52.55% 49.37% 41.22% EBITDA to Income R&D to Income 6.49% 6.95% 8.00% 14-Aug-19 2019-20 Q1 results
Slide 5: Income Comparison
INCOME COMPARISON INR Million 3,000.00 2,570.53 2,500.00 1,997.90 2,019.93 2,000.00 1,500.00 1,000.00 500.00 - Q1 Jun 18 Q4 Mar 19 Q1 Jun 19 14-Aug-19 2019-20 Q1 results
Slide 6: Profit Comparison
PROFIT COMPARISON INR Million 800.00 700.00 680.47 600.00 571.43 500.00 387.73 400.00 300.00 200.00 100.00 - Q1 Jun 18 Q4 Mar 19 Q1 Jun 19 14-Aug-19 2019-20 Q1 results
Slide 7: EBIDTA Comparison
EBIDTA COMPARISON INR Million 1,200.00 1,090.48 1,000.00 930.39 800.00 663.59 600.00 400.00 200.00 - Q1 Jun 18 Q4 Mar 19 Q1 Jun 19 14-Aug-19 2019-20 Q1 results
Slide 8: R & D – Expenditure
R & D – EXPENDITURE INR Million 200.00 178.69 180.00 159.89 160.00 140.00 131.01 120.00 100.00 80.00 60.00 40.00 20.00 - Q1 Jun 18 Q4 Mar 19 Q1 Jun 19 14-Aug-19 2019-20 Q1 results
Slide 9: Pre-R&D EBIDTA
PRE-R&D EBIDTA INR Million 1,400.00 1,269.17 1,200.00 1,061.41 1,000.00 823.47 800.00 600.00 400.00 200.00 - Q1 Jun 18 Q4 Mar 19 Q1 Jun 19 14-Aug-19 2019-20 Q1 results
Slide 10: Pre-R&D Cashflow
PRE-R&D CASHFLOW INR Million 1,000.00 913.79 900.00 800.00 757.95 700.00 602.70 600.00 500.00 400.00 300.00 200.00 100.00 - Q1 Jun 18 Q4 Mar 19 Q1 Jun 19 14-Aug-19 2019-20 Q1 results
Slide 11: Financial Snapshot
Financial Snapshot All figures are in INR Million, other than ratios and EPS 14-Aug-19 2019-20 Q1 results
Slide 12: News Updates
News Updates • SUVN-502 Phase 2A clinical trial, indicated for patients with moderate Alzheimer’s undertaken in USA completed with the Last Patient Last Visit (LPLV) on May 23, 2019. • The completed clinical trial had an enrollment of 564 patients against the target of 537 patients in the study. • T
Slide 13: News Updates
News Updates • During the period Suven secures 10 product patents covering regions/countries – Europe, India, Israel, Japan, Macau, Mexico, New Zealand, Sri Lanka and USA. • SUVN-G3031 Phase 2 clinical trial, indicated for Narcolepsy (with and without Cataplexy), initiated in USA with an estimated e
Suven Life Sciences — Q1 FY2020 Earnings Presentation on 6ix